comparemela.com
Home
Live Updates
Decreasing Grade 3/4 Infections, Limited Hospitalizations Un
Decreasing Grade 3/4 Infections, Limited Hospitalizations Un
Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma
Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.
Related Keywords
New York ,
United States ,
American ,
Sundar Jagannath ,
Tisch Cancer Institute Of Mount Sinai ,
Multiple Myeloma ,
Medical Oncology ,
Tisch Cancer Institute ,
Mount Sinai ,
Phase 1 2 Linker Mm1 Trial ,
Nct03761108 ,
Linvoseltamab ,
Regn5458 ,
Bbs ,